C-ring cannabinoid lactones: A novel cannabinergic chemotype

ACS Medicinal Chemistry Letters

Volumn 5, Issue 4, 2014, Pages 400-404

  Sharma, Rishi ^a,b   Nikas, Spyros P ^a   Guo, Jason Jianxin ^a   Mallipeddi, Srikrishnan ^a   Wood, Jodianne T ^a   Makriyannis, Alexandros ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b MicroConstants Inc   (United States)

Author keywords

Baeyer Villiger rearrangement; Cannabinoids; lactones

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DELTA8 TETRAHYDROCANNABINOL DERIVATIVE; ESTERASE; LACTONE DERIVATIVE;

ARTICLE; BAEYER VILLIGER REACTION; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CYCLIZATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; STATIC ELECTRICITY; STEREOCHEMISTRY;

EID: 84898035083     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml4005304     Document Type: Article

References (34)

1. Mechoulam, R.; Hanus, L. A historical overview of chemical research on cannabinoids Chem. Phys. Lipids 2000, 108, 1-13
2. Devane, W. A.; Dysarz, F. A., III; Johnson, M. R.; Melvin, L. S.; Howlett, A. C. Determination and characterization of a cannabinoid receptor in rat brain Mol. Pharmacol. 1988, 34, 605-613
3. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids Nature 1993, 365, 61-65
4. Pavlopoulos, S.; Thakur, G. A.; Nikas, S. P.; Makriyannis, A. Cannabinoid receptors as therapeutic targets Curr. Pharm. Des. 2006, 12, 1751-1769
5. Pertwee, R. G. Pharmacology of cannabinoid CB1 and CB2 receptors Pharmacol. Ther. 1997, 74, 129-180
6. Buchwald, A.; Derendorf, H.; Ji, F.; Nagaraja, N. Y.; Wu, W. M.; Bodor, N. Soft cannabinoid analogues as potential anti-glaucoma agents Pharmazie 2002, 57, 108-114
7. Hwang, J.; Adamson, C.; Butler, D.; Janero, D. R.; Makriyannis, A.; Bahr, B. A. Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality Life Sci. 2010, 86, 615-623
8. Jarvinen, T.; Pate, D. W.; Laine, K. Cannabinoids in the treatment of glaucoma Pharmacol. Ther. 2002, 95, 203-220
9. Karst, M.; Wippermann, S.; Ahrens, J. Role of cannabinoids in the treatment of pain and (painful) spasticity Drugs 2010, 70, 2409-2438
10. Lu, D.; Vemuri, V. K.; Duclos, R. I., Jr.; Makriyannis, A. The cannabinergic system as a target for anti-inflammatory therapies Curr. Top. Med. Chem. 2006, 6, 1401-1426
11. Marco, E. M.; Romero-Zerbo, S. Y.; Viveros, M. P.; Bermudez-Silva, F. J. The role of the endocannabinoid system in eating disorders: pharmacological implications Behav. Pharmacol. 2012, 23, 526-536
12. Pertwee, R. G. Cannabinoid receptors and pain Prog. Neurobiol. 2001, 63, 569-611
13. Grotenhermen, F. Pharmacokinetics and pharmacodynamics of cannabinoids Clin. Pharmacokinet. 2003, 42, 327-360
14. Bodor, N.; Buchwald, P. Soft drug design: general principles and recent applications Med. Res. Rev. 2000, 20, 58-101
15. Bodor, N.; Buchwald, P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems AAPS J. 2005, 7, E820-833
16. Bodor, N.; Buchwald, P. Recent advances in retrometabolic drug design (RMDD) and development Pharmazie 2010, 65, 395-403
17. Minutolo, F.; Cascio, M. G.; Carboni, I.; Bisogno, T.; Prota, G.; Bertini, S.; Digiacomo, M.; Bifulco, M.; Di Marzo, V.; Macchia, M. Metabolically labile cannabinoid esters: a 'soft drug' approach for the development of cannabinoid-based therapeutic drugs Bioorg. Med. Chem. Lett. 2007, 17, 4878-4881
18. Buchwald, A.; Browne, C. E.; Wu, W. M.; Ji, F.; Bodor, N. Soft cannabinoid analogues as potential anti-glaucoma agents Pharmazie 2000, 55, 196-201
19. Sharma, R.; Nikas, S. P.; Paronis, C. A.; Wood, J. T.; Halikhedkar, A.; Guo, J. J.; Thakur, G. A.; Kulkarni, S.; Benchama, O.; Raghav, J. G.; Gifford, R. S.; Jarbe, T. U.; Bergman, J.; Makriyannis, A. Controlled-deactivation cannabinergic ligands J. Med. Chem. 2013, 56, 10142-10157
20. Thakur, G. A.; Nikas, S. P.; Li, C.; Makriyannis, A. Structural requirements for cannabinoid receptor probes Handb. Exp. Pharmacol. 2005, 209-246
21. Thakur, G. A.; Nikas, S. P.; Makriyannis, A. CB1 cannabinoid receptor ligands Mini-Rev. Med. Chem. 2005, 5, 631-640
22. Nikas, S. P.; Thakur, G. A.; Parrish, D.; Alapafuja, S. O.; Huestis, M. A.; Makriyannis, A. A concise methodology for the synthesis of (-)-delta(9)-tetrahydrocannabinol and (-)-delta(9)-tetrahydrocannabivarin metabolites and their regiospecifically deuterated analogs Tetrahedron 2007, 63, 8112-8123
23. Nikas, S. P.; Alapafuja, S. O.; Papanastasiou, I.; Paronis, C. A.; Shukla, V. G.; Papahatjis, D. P.; Bowman, A. L.; Halikhedkar, A.; Han, X.; Makriyannis, A. Novel 1′,1′-chain substituted hexahydrocannabinols: 9beta-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist J. Med. Chem. 2010, 53, 6996-7010
24. Archer, R. A.; Blanchard, W. B.; Day, W. A.; Johnson, D. W.; Lavagnino, E. R.; Ryan, C. W.; Baldwin, J. E. Cannabinoids. 3. Synthetic approaches to 9-ketocannabinoids. Total synthesis of nabilone J. Org. Chem. 1977, 42, 2277-2284
25. Maitraie, D.; Hung, C. F.; Tu, H. Y.; Liou, Y. T.; Wei, B. L.; Yang, S. C.; Wang, J. P.; Lin, C. N. Synthesis, anti-inflammatory, and antioxidant activities of 18beta-glycyrrhetinic acid derivatives as chemical mediators and xanthine oxidase inhibitors Bioorg. Med. Chem. 2009, 17, 2785-2792
26. Papahatjis, D. P.; Nahmias, V. R.; Nikas, S. P.; Schimpgen, M.; Makriyannis, A. Design and synthesis of (13 S)-methyl-substituted arachidonic acid analogues: Templates for novel endocannabinoids Chem. - Eur. J. 2010, 16, 4091-4099
27. Ono, M.; Zhao, X. Y.; Shida, Y.; Akita, H. Delta-Lactone formation from delta-hydroxy-trans-alpha,beta-unsaturated carboxylic acids accompanied by trans-cis isomerization: synthesis of (-)delta-tetra- O -acetylosmundalin Tetrahedron 2007, 63, 10140-10148
28. Kurti, L.; Czako, B. Strategic Applications of Named Reactions in Organic Synthesis; Elsevier Academic Press: New York, 2005; pp 28-29, 540-542.
29. Goodman, R. M.; Kishi, Y. Experimental support for the primary stereoelectronic effect governing Baeyer-Villiger oxidation and Criegee rearrangement J. Am. Chem. Soc. 1998, 120, 9392-9393
30. Papahatjis, D. P.; Nahmias, V. R.; Nikas, S. P.; Andreou, T.; Alapafuja, S. O.; Tsotinis, A.; Guo, J.; Fan, P.; Makriyannis, A. C1′-cycloalkyl side chain pharmacophore in tetrahydrocannabinols J. Med. Chem. 2007, 50, 4048-4060
31. Shire, D.; Calandra, B.; Rinaldi-Carmona, M.; Oustric, D.; Pessegue, B.; Bonnin-Cabanne, O.; Le Fur, G.; Caput, D.; Ferrara, P. Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor Biochim. Biophys. Acta 1996, 1307, 132-136
32. Khanolkar, A. D.; Lu, D.; Ibrahim, M.; Duclos, R. I., Jr.; Thakur, G. A.; Malan, T. P., Jr.; Porreca, F.; Veerappan, V.; Tian, X.; George, C.; Parrish, D. A.; Papahatjis, D. P.; Makriyannis, A. Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity J. Med. Chem. 2007, 50, 6493-6500
33. Mukherjee, S.; Adams, M.; Whiteaker, K.; Daza, A.; Kage, K.; Cassar, S.; Meyer, M.; Yao, B. B. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors Eur. J. Pharmacol. 2004, 505, 1-9
34. Han, S.; Thatte, J.; Buzard, D. J.; Jones, R. M. Therapeutic utility of cannabinoid receptor type 2 (CB) selective agonists J. Med. Chem. 2013, 56, 8224-8256